TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
April 15, 2024 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,...
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
April 08, 2024 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,...
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
March 21, 2024 16:05 ET
|
TELA Bio, Inc.
MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
March 21, 2024 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,...
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
March 20, 2024 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,...
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2024 16:05 ET
|
TELA Bio, Inc.
MALVERN, Pa., Feb. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024 16:05 ET
|
TELA Bio, Inc.
MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2023 16:05 ET
|
TELA Bio, Inc.
MALVERN, Pa., Dec. 15, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio to Take Part in Connecting the Dots
December 05, 2023 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...